Company intelligence / Profile preview

Oncomatryx

Ownership: Private
Development stage: Other

Overview

OMTX705, their lead ADC targeting FAP, has entered Phase 1 clinical trials after showing significant inhibition of pancreatic tumor growth in preclinical studies. The company has successfully raised €25 million to fund Phase Ib-II clinical trials.

Therapeutic areas: Oncology
Modalities: Antibody-Drug Conjugates (ADCs)Monoclonal antibodiesRecombinant proteins
Industry: Biotech

Drug pipeline

7 assets

OMTX705

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Oncomatryx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncomatryx.